Modulation of endothelin and nitric oxide: a rational approach to improve canine hepatic microcirculation.
ET receptor blocker (TAK-044) and NO donor (FK409) were used to improve the hepatic microcirculation following ischemia-reperfusion injury. In the first experiment (60 minutes of ischemia), 15 dogs were divided into three groups: group A (control), saline; group B, TAK 5 mg/kg; and group C, FK 0.4 mg/kg. In the second experiment (90 minutes of ischemia), 38 dogs were divided into six groups that underwent 90 minutes of hepatic ischemia followed by reperfusion: group I (control), saline only; group II, TAK 5 mg/kg and FK 3.2 mg/kg; group III, TAK 5 mg/kg and FK 0.4 mg/kg; group IV, TAK 5 mg/kg; group V, FK 0.4 mg/kg; and group VI, FK3.2 mg/kg. All drugs were administered through the portal vein. Following 60 minutes of ischemia, both FK and TAK produced significant improvement in hepatic microcirculation and enzymatic status when compared with the control group. After 90 minutes of ischemia, low doses of FK and TAK significantly improved hepatic microcirculation and reduced portal pressure following reperfusion in group III compared with group I. Leakage of hepatic enzymes was prevented and tissue injury score was significantly lower in group III. In group VI, early protection was obtained to some extent; however, blood pressure was reduced significantly following reperfusion compared with group I. In contrast, hepatocellular function deteriorated and the tissue injury score was higher in group II animals. TAK pretreatment with low doses of FK provided the best protection for the hepatic microcirculation in ischemia-reperfusion injury of the liver.
Dhar
D K
DK
Second Department of Surgery, Shimane Medical University, Izumo, Japan.
Yamanoi
A
A
Ohmori
H
H
Nakashima
Y
Y
Yamamoto
A
A
Osama
N E
NE
Kubota
H
H
Kohno
H
H
Nagasue
N
N
D000818:Animals; D001794:Blood Pressure; D003402:Creatine Kinase / Q000378:metabolism; D004285:Dogs; D016232:Endothelins / Q000502:physiology*; D005260:Female; D007511:Ischemia / Q000188:drug therapy* / Q000378:metabolism; D007527:Isoenzymes; D008099:Liver / Q000201:enzymology / Q000473:pathology; D008102:Liver Circulation / Q000187:drug effects*; D008297:Male; D008833:Microcirculation / Q000187:drug effects; D009569:Nitric Oxide / Q000502:physiology*; D009574:Nitro Compounds / Q000627:therapeutic use; D010456:Peptides, Cyclic / Q000627:therapeutic use; D015427:Reperfusion Injury / Q000517:prevention & control*
D016232:Endothelins; D007527:Isoenzymes; D009574:Nitro Compounds; D010456:Peptides, Cyclic; C088196:TAK 044; D009569:Nitric Oxide; C061872:FK 409; D003402:Creatine Kinase